Picture of virus under microscope

Research under the microscope...

The Strathprints institutional repository is a digital archive of University of Strathclyde research outputs.

Strathprints serves world leading Open Access research by the University of Strathclyde, including research by the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), where research centres such as the Industrial Biotechnology Innovation Centre (IBioIC), the Cancer Research UK Formulation Unit, SeaBioTech and the Centre for Biophotonics are based.

Explore SIPBS research

PLGA nanoparticles stabilized with cationic surfactant : safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat

Bhardwaj, V. and Ankola, D.D. and Gupta, S.C. and Schneider, M. and Lehr, C.M. and Kumar, M.N.V.R. (2009) PLGA nanoparticles stabilized with cationic surfactant : safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharmaceutical Research, 26 (11). pp. 2495-2503. ISSN 0724-8741

Full text not available in this repository. (Request a copy from the Strathclyde author)

Abstract

Purpose This study was carried out to formulate poly(lactide-co-glycolide) (PLGA) nanoparticles using a quaternary ammonium salt didodecyl dimethylammonium bromide (DMAB) and checking their utility to deliver paclitaxel by oral route. Methods Particles were prepared by emulsion solvent diffusion evaporation method. DMAB and particles stabilized with it were evaluated by MTT and LDH cytotoxicity assays. Paclitaxel was encapsulated in these nanoparticles and evaluated in a chemical carcinogenesis model in Sprague Dawley rats. Results MTT and LDH assays showed the surfactant to be safe to in vitro cell cultures at concentrations <33 μM. PLGA nanoparticles prepared using this stabilizer were also found to be non-toxic to cell lines for the duration of the study. When administered orally to rats bearing chemically induced breast cancer, nanoparticles were equally effective/better than intravenous paclitaxel in cremophor EL at 50% lower dose. Conclusions This study proves the safety and utility of DMAB in stabilizing preformed polymers like PLGA resulting in nanoparticles. This preliminary data provides a proof of concept of enabling oral chemotherapy by efficacy enhancement for paclitaxel.